Bioactive components conjugated to substrates of microneedle arrays
First Claim
Patent Images
1. A dissolvable microneedle array for transdermal insertion into a patient comprising:
- a substrate comprising a biocompatible material that forms base portion and a plurality of microneedles extending from the base portion; and
one or more bioactive components conjugated to the biocompatible material,wherein the one or more bioactive components are cleavable in vivo by an enzyme to release the bioactive component from the biocompatible material, or the bioactive component retains function when conjugated to the biocompatible material.
1 Assignment
0 Petitions
Accused Products
Abstract
Microneedle arrays and methods of forming the same can include one or more bioactive components bonded to a biocompatible material such that the one or more bioactive components are cleavable in vivo to release the bioactive component from the biocompatible material.
-
Citations
64 Claims
-
1. A dissolvable microneedle array for transdermal insertion into a patient comprising:
-
a substrate comprising a biocompatible material that forms base portion and a plurality of microneedles extending from the base portion; and one or more bioactive components conjugated to the biocompatible material, wherein the one or more bioactive components are cleavable in vivo by an enzyme to release the bioactive component from the biocompatible material, or the bioactive component retains function when conjugated to the biocompatible material. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
-
14. A dissolvable microneedle array for transdermal insertion into a patient comprising:
-
a substrate comprising a biocompatible material that forms base portion and a plurality of microneedles extending from the base portion; and a first bioactive component conjugated to the biocompatible material, the bioactive component being Doxorubicin, wherein the first bioactive component is cleavable in vivo by an enzyme to release the first bioactive component from the biocompatible material, or the first bioactive component retains function when conjugated to the biocompatible material. - View Dependent Claims (15, 16, 17, 18, 19, 20, 21, 22)
-
-
23. A dissolvable microneedle array for transdermal insertion into a patient comprising:
-
a substrate comprising a biocompatible material that forms base portion and a plurality of microneedles extending from the base portion; and one or more bioactive components conjugated to the biocompatible material, wherein the one or more bioactive components are cleavable in vivo to release the bioactive component from the biocompatible material, or the bioactive component retains function when conjugated to the biocompatible material, and wherein the one or more bioactive components are bonded to the biocompatible material by a disulfide bond which is cleavable in vivo by an enzyme. - View Dependent Claims (24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)
-
-
36. A dissolvable microneedle array for transdermal insertion into a patient comprising:
-
a substrate comprising a biocompatible material that forms base portion and a plurality of microneedles extending from the base portion; and one or more bioactive components conjugated to the biocompatible material, wherein the one or more bioactive components are cleavable in vivo by an enzyme to release the bioactive component from the biocompatible material, or the bioactive component retains function when conjugated to the biocompatible material, and wherein the one or more bioactive component comprises at least one viral vector wherein the bioactive component is bonded to the biocompatible material by a disulfide bond which is cleavable in vivo by an enzyme. - View Dependent Claims (37, 38, 39, 40, 41, 42, 43, 44, 45)
-
-
46. A dissolvable microneedle array for transdermal insertion into a patient comprising:
-
a substrate comprising a biocompatible material that forms base portion and a plurality of microneedles extending from the base portion; and one or more bioactive components conjugated to the biocompatible material, wherein the one or more bioactive components are cleavable in vivo to release the bioactive component from the biocompatible material, or the bioactive component retains function when conjugated to the biocompatible material, wherein the one or more bioactive components comprise at least two different bioactive components conjugated to the biocompatible material, and wherein the bioactive component comprises an antigen and an adjuvant for a vaccine application. - View Dependent Claims (47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)
-
-
58. A dissolvable microneedle array for transdermal insertion into a patient comprising:
-
a substrate comprising a biocompatible material that forms base portion and a plurality of microneedles extending from the base portion; and a first bioactive component conjugated to the biocompatible material, the bioactive component being Doxorubicin, wherein the first bioactive component is cleavable in vivo to release the first bioactive component from the biocompatible material, or the first bioactive component retains function when conjugated to the biocompatible material, and wherein the second bioactive component is mixed into the biocompatible material wherein the bioactive components are bonded to the biocompatible material by a disulfide bond which is cleavable in vivo by an enzyme. - View Dependent Claims (59, 60, 61, 62, 63, 64)
-
Specification